09:29 AM EDT, 07/18/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) shares were falling 25% in recent Friday pre-market activity after Bloomberg reported that another person has died from acute liver failure after receiving one of the company's gene therapies.

Bloomberg quoted a Sarepta spokesperson as saying a person died of acute liver failure last month in a trial of a gene therapy to treat limb-girdle muscular dystrophy.

The spokesperson said Sarepta told regulators about the death "in an appropriate and timely manner," the report said.

Sarepta had previously said that two people recently died of acute liver failure while being treated with Elevidys, a gene therapy for Duchenne muscular dystrophy, the report added.

Sarepta didn't immediately respond to a request for comment by MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)